{"title":"Prediction of Cancer Treatment Using Advancements in Machine Learning.","authors":"Arun Kumar Singh, Jingjing Ling, Rishabha Malviya","doi":"10.2174/1574892818666221018091415","DOIUrl":null,"url":null,"abstract":"<p><p>Many cancer patients die due to their treatment failing because of their disease's resistance to chemotherapy and other forms of radiation therapy. Resistance may develop at any stage of therapy, even at the beginning. Several factors influence current therapy, including the type of cancer and the existence of genetic abnormalities. The response to treatment is not always predicted by the existence of a genetic mutation and might vary for various cancer subtypes. It is clear that cancer patients must be assigned a particular treatment or combination of drugs based on prediction models. Preliminary studies utilizing artificial intelligence-based prediction models have shown promising results. Building therapeutically useful models is still difficult despite enormous increases in computer capacity due to the lack of adequate clinically important pharmacogenomics data. Machine learning is the most widely used branch of artificial intelligence. Here, we review the current state in the area of using machine learning to predict treatment response. In addition, examples of machine learning algorithms being employed in clinical practice are offered.</p>","PeriodicalId":20774,"journal":{"name":"Recent patents on anti-cancer drug discovery","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-cancer drug discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1574892818666221018091415","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Many cancer patients die due to their treatment failing because of their disease's resistance to chemotherapy and other forms of radiation therapy. Resistance may develop at any stage of therapy, even at the beginning. Several factors influence current therapy, including the type of cancer and the existence of genetic abnormalities. The response to treatment is not always predicted by the existence of a genetic mutation and might vary for various cancer subtypes. It is clear that cancer patients must be assigned a particular treatment or combination of drugs based on prediction models. Preliminary studies utilizing artificial intelligence-based prediction models have shown promising results. Building therapeutically useful models is still difficult despite enormous increases in computer capacity due to the lack of adequate clinically important pharmacogenomics data. Machine learning is the most widely used branch of artificial intelligence. Here, we review the current state in the area of using machine learning to predict treatment response. In addition, examples of machine learning algorithms being employed in clinical practice are offered.
期刊介绍:
Aims & Scope
Recent Patents on Anti-Cancer Drug Discovery publishes review and research articles that reflect or deal with studies in relation to a patent, application of reported patents in a study, discussion of comparison of results regarding application of a given patent, etc., and also guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs, targets & predictive biomarkers & drug efficacy biomarkers. The journal also publishes book reviews of eBooks and books on anti-cancer drug discovery. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-cancer drug discovery.